Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce tregs and MDSCs number

Journal of Immunotherapy

Volumn 37, Issue 9, 2014, Pages 427-439

  Rossowska, Joanna ^a   Pajtasz Piasecka, Elzbieta ^a   Anger, Natalia ^a   Wojas Turek, Justyna ^a   Kicielińska, Jagoda ^a   Piasecki, Egbert ^a   Dus̈, Danuta ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antitumor immunotherapy; Cyclophosphamide; Experimental MC38 colon carcinoma; IL 12 transduced dendritic cells; Myeloid derived suppressor cells

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR ANTIGEN; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SIZE; CELL LYSATE; COLON CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SPLEEN; SPLEEN CELL; SUPPRESSOR CELL; THERAPY EFFECT; ANIMAL; BIOLOGICAL THERAPY; C57BL MOUSE; COLONIC NEOPLASMS; CYTOLOGY; DRUG EFFECTS; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CELL- AND TISSUE-BASED THERAPY; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOKINES; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY; MICE, INBRED C57BL; MYELOID CELLS; SPLEEN; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC; TUMOR BURDEN;

EID: 84916603560     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000054     Document Type: Article

References (41)

1. Lasaro MO, Ertl HC. Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol. 2010;22:385-390.
2. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009;21:200-208.
3. Pajtasz-Piasecka E, IndrováM. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy. 2010;2:257-268.
4. Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013; 119:421-475.
5. Kao J, Ko EC, Eisenstein S, et al. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol. 2011;77:12-19.
6. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7:880-887.
7. Welters MJ, Piersma SJ, van der Burg SH. T-regulatory cells in tumour-specific vaccination strategies. Expert Opin Biol Ther. 2008;8:1365-1379.
8. Schabowsky RH, Madireddi S, Sharma R, et al. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs. 2007;8:1002-1008.
9. Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301-6311.
10. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9: 162-174.
11. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49-59.
12. Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 2009;69:5514-5521.
13. Nagaraj S, Gabrilovich DI. Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol. 2012;22:282-288.
14. Bak SP, Alonso A, Turk MJ, et al. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol. 2008;46:258-268.
15. Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182:5693-5701.
16. Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70:68-77.
17. Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68:5439-5449.
18. Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012;189:5602-5611.
19. Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33:369-383.
20. Liu JY, Wu Y, Zhang XS, et al. Single administration of low dose cyclophosphamide auguments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother. 2007; 56:1597-1604.
21. Mikys?kováR, IndrováM, PollákováV, et al. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. J Immunother. 2012;35:374-384.
22. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22.
23. Breckpot K, Heirman C, Neyns B, et al. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med. 2004;6:1175-1188.
24. Rossowska J, Pajtasz-Piasecka E, Rys̈nik O, et al. Generation of antitumor response by IL-2-transduced JAWS II dendritic cells. Immunobiology. 2011;216:1074-1084.
25. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev Immunol. 2003; 3:133-146.
26. Steding CE, Wu ST, Zhang Y, et al. The role of interleukin-1 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology. 2011; 133:221-238.
27. Akiyama Y, Maruyama K, Watanabe M, et al. Retroviralmediated IL-12 gene transduction into human CD34+ cell derived dendritic cells. Int J Oncol. 2002;21:509-514.
28. Pajtasz-Piasecka E, Rossowska J, Szyda A, et al. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes. Oncol Rep. 2007;17:1249-1257.
29. Nishioka Y, Hirao M, Robbins PD, et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999;59:4035-4041.
30. Pajtasz-Piasecka E, Szyda A, Rossowska J, et al. Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha). 2004;50:7-14.
31. Rossowska J, Pajtasz-Piasecka E, Szyda A, et al. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response. Folia Hist Cytobiol. 2007;45:349-355.
32. Rossowska J, Pajtasz-Piasecka E, Szyda A, et al. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo. Oncol Rep. 2009;21:1539-1549.
33. Malvicini M, Piccioni F, Bayo J, et al. Chemoimmunotherapy for advanced gastrointestinal carcinomas: a successful combination of gene therapy and cyclophosphamide. Oncoimmunology. 2012;1:1626-1628.
34. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013;62:203-216.
35. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001;61:7530-7535.
36. Alfaro C, Perez-Gracia JL, Suarez N, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol. 2011;187:6130-6142.
37. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 2005;65:5958-5964.
38. Malvicini M, Ingolotti M, Piccioni F, et al. Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. MolOncol. 2011; 5:242-255.
39. Medina-Echeverz J, Fioravanti J, Zabala M, et al. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol. 2011;186:807-815.
40. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumorassociated neutrophil phenotype by TGF-b: "N1" versus "N2" TAN. Cancer Cell. 2009;16:183-194.
41. Roux S, Apetoh L, Chalmin F, et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest. 2008;118:3751-3761.